文献速递腹部介入CTDSA

肝动脉造影与CT中碘油摄取分析用于鉴别肝硬化肝脏恶性与良性肝细胞结节

Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
PubMed 文献 · Eur Radiol · 2019-06-24

本回顾性研究纳入60例肝硬化且MRI诊断为LI-RADS 3或4病变的患者,评估碘油造影及造影后平扫CT对肝细胞癌与良性结节的鉴别价值。结果显示造影清晰可见(敏感度100%、特异度87.5%)联合CT均匀或腔隙样碘油强化(敏感度86.1%、特异度100%)可诊断肝细胞癌,作者认为明确诊断可能无需额外活检。

要点

  • MRI诊断为LI-RADS 3或4的肝硬化病变,造影清晰可见联合CT均匀或腔隙样碘油强化可鉴别肝细胞癌与良性结节。
  • 造影清晰可见诊断肝细胞癌的敏感度为100%、特异度为87.5%。
  • CT均匀或腔隙样碘油强化诊断肝细胞癌的敏感度为86.1%、特异度为100%。

核心结论

  • 碘油造影中清晰可见的病变及造影后平扫CT中均匀或腔隙样强化,可将MRI分类为LI-RADS 3或4的肝内病变鉴别为良性或恶性,作者认为明确诊断可能无需额外活检。

研究设计与样本

  • 回顾性研究纳入60例肝硬化患者(男42例[70.0%]、女18例[30.0%],平均年龄61±9.1岁),均为MRI诊断LI-RADS 3或4病变并接受碘油造影、介入后平扫CT及肝活检;由两名独立放射科医生评估造影表现、对比强化、碘油摄取及平扫CT形态参数,并考虑甲胎蛋白水平及既往肝脏情况。

关键影像表现/征象

  • 造影中病变清晰可见联合连续CT上均匀或腔隙样碘油强化可诊断为肝硬化肝细胞癌。
  • 病变形态为圆形或卵圆形(p < 0.001)及强烈对比强化(p < 0.001)是次要特征,可辅助诊断。
  • 肝细胞癌患者CT上病变尺寸更大(p = 0.026)。

诊断标准与关键数值

  • 造影清晰可见诊断肝细胞癌的敏感度100%、特异度87.5%。
  • CT均匀或腔隙样碘油强化诊断肝细胞癌的敏感度86.1%、特异度100%。

临床应用与阅片要点

  • 对MRI分类为LI-RADS 3或4的肝硬化病变,可结合碘油造影清晰可见及造影后平扫CT均匀或腔隙样强化进行鉴别。
  • 圆形或卵圆形形态及强烈对比强化可作为辅助诊断的次要特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic value of Lipiodol distribution in angiography and CT to differentiate between hepatocellular carcinoma (HCC) and benign nodules of LI-RADS 3 and 4 lesions observed in MRI of liver cirrhosis.

METHODS: This retrospective study included all patients with liver cirrhosis who had diagnosis of LI-RADS 3 or 4 lesions by MRI who underwent a Lipiodol-based angiography and post-interventional unenhanced CT- and liver biopsy. Two independent radiologists evaluated appearance, contrast enhancement, Lipiodol uptake in angiography, and morphological parameters (size, form, and density) of the lesions in unenhanced post-angiography CT. α-Fetoprotein (AFP) levels and pre-existing liver conditions were additionally taken into consideration. Differences between HCC lesions and benign nodules were analyzed. Sensitivity and specificity were calculated. P < 0.05 was considered as statistically significant.

RESULTS: Of 60 patients (men, n = 42 [70.0%]; women, 18 [30.0%]; mean age, 61 ± 9.1 years) 36 (60.0%) had HCC and 24 (40.0%) benign nodules. Clear visibility in angiography (sensitivity [se], 100%; specificity [sp], 87.5%) with homogeneous or lacunar Lipiodol enhancement (se, 86.1%; sp, 100%) in consecutive CT can be diagnosed as HCC lesions in cirrhotic liver. Lesion form (p < 0.001), round or oval, and intense contrast (p < 0.001) are minor features which can facilitate the findings. Furthermore, patients with HCC showed a larger lesion size in CT (p = 0.026).

CONCLUSION: Clearly detectable lesions in Lipiodol-based angiography and a homogeneous or lacunar enhancement in post-angiographic non-contrast CT allow for differentiation of intrahepatic lesions classified as LI-RADS 3 or 4 into benign vs. malign liver lesions with high sensitivity and specificity in patients with liver cirrhosis. Definite diagnosis may not require an additional biopsy.

KEY POINTS: • Combination of clear visibility in Lipiodol-based angiography and homogeneous or lacunar enhancement in following native CT scan is HCC-defining. • In lesions classified with MRI as LI-RADS 3 or 4, evaluation based on Lipiodol angiography and following plain CT performed is highly sensitive and specific for the differentiation between HCC and benign nodules in a cirrhotic liver. • The results lead to an alternative pathway in the diagnosis of HCC in cirrhotic liver without the need of an additional liver biopsy.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Langenbach MC, Vogl TJ, von den Driesch I, et al. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver. Eur Radiol. 2019. PMID: 31236701. doi:10.1007/s00330-019-06297-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。